ABSTRACT
Among the flaviviruses, dengue, with its four serotypes, has spread throughout the tropics. The most advanced vaccines developed so far include live attenuated viruses, which have been tested in humans but none has been licensed. Preclinical testing of dengue vaccine candidates is performed initially in mice and in nonhuman primates. In the latter the main criteria used to assay protection are neutralizing antibodies elicited by the vaccine candidate and the magnitude and duration of peripheral viremia upon challenge of previously immunized animals. Towards the identification of wild-type viruses that could be used in challenge experiments a total of 31 rhesus monkeys were inoculated subcutaneously of wild dengue types 1, 2, and 3 viruses. The viremia caused by the different viruses was variable but it was possible to identify dengue viruses useful as challenge strains.
Subject(s)
Humans , Animals , Male , Female , Dengue Virus/classification , Dengue Virus/pathogenicity , Viremia/virology , Chlorocebus aethiops , Disease Models, Animal , Macaca mulatta/virology , Vero Cells/virologyABSTRACT
A chimeric yellow fever (YF)-dengue serotype 2 (dengue 2) virus was constructed by replacing the premembrane and envelope genes of the YF 17D virus with those from dengue 2 virus strains of Southeast Asian genotype. The virus grew to high titers in Vero cells and, after passage 2, was used for immunogenicity and attenuation studies in rhesus monkeys. Subcutaneous immunization of naive rhesus monkeys with the 17D-D2 chimeric virus induced a neutralizing antibody response associated with the protection of 6 of 7 monkeys against viremia by wild-type dengue 2 virus. Neutralizing antibody titers to dengue 2 were significantly lower in YF-immune animals than in YF-naive monkeys and protection against challenge with wild-type dengue 2 virus was observed in only 2 of 11 YF-immune monkeys. An anamnestic response to dengue 2, indicated by a sharp increase of neutralizing antibody titers, was observed in the majority of the monkeys after challenge with wild-type virus. Virus attenuation was demonstrated using the standard monkey neurovirulence test. The 17D-D2 chimera caused significantly fewer histological lesions than the YF 17DD virus. The attenuated phenotype could also be inferred from the limited viremias compared to the YF 17DD vaccine. Overall, these results provide further support for the use of chimeric viruses for the development of a new live tetravalent dengue vaccine.
Subject(s)
Animals , Male , Female , Antibodies, Viral/biosynthesis , Viremia/immunology , Dengue Virus/immunology , Yellow fever virus/immunology , Amino Acid Sequence , Antibodies, Viral/immunology , Chlorocebus aethiops , Macaca mulatta , Molecular Sequence Data , Neutralization Tests , Recombination, Genetic , Reverse Transcriptase Polymerase Chain Reaction , Vero Cells , Dengue Virus/genetics , Yellow fever virus/geneticsABSTRACT
Amphiphilic proteins were partially purified from culture-derived metacyclic trypomastigotes of the CL and Colombian strains and of the Dm 28c clone of T. cruzi by the use of Triton X-114. These proteins were subjected to one-and two-dimensional polyacrylamide electrophoresis in the presence of sodium dodecyl sulphate. Relatively simple protein profiles with only 5 to 6 major bands were obtained. The CL and Colombian strains produced at least one additional major protein band (86 kDa) compared to the Dm 28c proteins. Trypomastigote amphiphilic proteins displayed both electrophoretic mobilities and isoelectric points identical to those of two polypeptides precipitated by a rabbit antiserum which recognized metacyclic trypomastigote-specific surface antigens. The partial purification of the T. cruzi amphiphilic proteins with Triton X-114 may provide a simple preparative step for the study of these differentiation-related polypeptides, as well as for the study of strain-specific (glyco)proteins and of their possible biological role